Abacavir Sulfate, Dolutegravir and Lamivudine | VIIV Healthcare | ||
60mg/5mg/30mg; Tablet for Suspension |
More Than $1000 mn
|
||
Less Than 5
|
Less Than 5
|
||
Less Than 5
|
Less Than 5
|
||
None | None | ||
TRIUMEQ PD is a combination of dolutegravir (integrase strand transfer inhibitor [INSTI]), abacavir, and lamivudine (both nucleoside analogue reverse transcriptase inhibitors) indicated for the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 10 kg | |||
Yes
|
Triumeq PD | Patent 1 | Patent 2 |
---|---|---|
***** | ******* **** *** | *** ********* |
Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
---|---|---|---|---|---|
***** | *** \ ********* | -**- | *** ********* | ********* ******** | ******* *** **** (***** ******) *** *** **** |